# 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

> **NCT02038738** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ochsner Health System** · enrollment: 250 (estimated)

## Conditions studied

- Neuroendocrine
- Neuroendocrine Tumor
- Neuroendocrine Cancer
- Neuroendocrine Carcinoma
- Carcinoid
- Carcinoid Tumor
- Islet Cell Tumor
- Apudoma

## Interventions

- **DRUG:** 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.

## Key facts

- **NCT ID:** NCT02038738
- **Lead sponsor:** Ochsner Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2019-03
- **Final completion:** —
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2014-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038738, "68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02038738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*